proof3
GymAssessments
Online Coaching
Online CoachingOnline Coaches
Learn
Research ArticlesCoach's BlogNewsletter
AboutBook your free assessment
Research Breakdowns
November 2026

Retatrutide and Muscle: What the Weight-Loss Headlines Leave Out

What does retatrutide research tell us about liver fat, lean mass and muscle? proof3 explains the findings, limits and questions still worth asking.

Retatrutide gets people's attention. You may have heard it called “Reta,” seen a striking weight-loss number, or watched someone describe what it could mean for fatty liver disease.

We talked about it in our GLP-1 newsletter because we are interested, too. When something appears capable of changing body weight and body fat substantially, we want to understand it.

Then we want to ask the next question: what does that tell us about muscle and physical capability?

Retatrutide research has shown substantial reductions in weight and fat, but those findings do not establish that it prevents muscle loss or removes the need for strength training. A result about liver fat answers a different question from a result about muscle or strength.

That is the distinction we want readers to keep in mind. There is room to be interested in the research and precise about what it shows.

Why people call retatrutide a triple agonist

GLP-1 has become a catch-all term in everyday conversation about newer weight-loss medications. The drugs people group together do not all act in exactly the same way.

A receptor is a structure in the body that responds to a particular signal. An agonist activates a receptor. Those terms sound more complicated than the basic idea: different medications can act on different combinations of signals involved in appetite and metabolism.

Semaglutide acts on GLP-1 receptors. Tirzepatide acts on GLP-1 and GIP receptors. Retatrutide is being studied as a medication that acts on three: GLP-1, GIP and glucagon receptors.

Knowing that helps explain why retatrutide is described as a triple agonist. It does not, by itself, tell you which treatment is right for a person or whether a drug preserves muscle. Those are questions for evidence, not for counting receptors.

As of October 16, 2026, Lilly describes retatrutide as investigational and not FDA-approved, with its safety and effectiveness still being evaluated. Its research program includes phase 3 trials. See Lilly's current retatrutide information.

That status matters when people discuss it as though it were simply another routine treatment option. We are discussing research here. Medication choices and access belong in a conversation with a qualified clinician.

We also want to avoid reducing the biology to a slogan about turning on a fat-burning switch. It may be memorable, but it tells you very little about what was measured, who benefited or what problems occurred during treatment.

The study is where the useful questions begin.

What the liver-fat study actually measured

The research highlighted in our newsletter included a 2024 phase 2a study of 98 people with metabolic dysfunction-associated steatotic liver disease, a condition involving excess liver fat. Researchers measured liver fat using MRI.

After 24 weeks, the average relative reductions from starting liver-fat levels were substantial in the retatrutide groups. Here are the reported results across all five study groups:

Table: average relative change in liver fat at 24 weeks. Retatrutide 1 mg -42.9%, 4 mg -57.0%, 8 mg -81.4%, 12 mg -82.4%, placebo +0.3%.

These were study doses, not dosing advice. The percentages describe change in liver fat relative to each person's starting measurement; they are not percentages of total body weight lost. Read the study in Nature Medicine.

Why does that distinction deserve space? Because a large percentage can travel a long way online after the measurement it describes has disappeared.

Liver fat, total body fat and body weight are related subjects, but they are different measurements. A finding about one cannot simply be substituted for another.

The same applies when a headline moves from an improvement in a measurement to a claim that a disease has been erased. We would want to know exactly what definition the researchers used, what follow-up they completed and which health outcomes they assessed.

There is plenty to find interesting in a substantial liver-fat reduction without making it answer every other question about the treatment.

There is body-composition research, too

We should not imply that liver-fat findings are the only evidence available.

A separate retatrutide body-composition substudy, published in 2025, examined adults with type 2 diabetes over 36 weeks. It used DXA scans, which estimate body composition. Of 189 people enrolled in the substudy, 103 completed treatment and had both the starting and week-36 scans.

The researchers reported reductions in body fat and described the proportion of weight lost as lean mass as similar to other obesity treatments. The study was funded by Eli Lilly, and its authors disclosed being company employees and shareholders. Read the body-composition substudy.

That adds useful evidence. It does not justify calling retatrutide a muscle-preserving drug on the basis of these findings alone.

Remember what lean mass means: it includes muscle and other non-fat soft tissues. It is not a direct count of muscle tissue, and a change in it is not the same thing as a test of physical strength.

We would also be careful about comparing a percentage from this study with a percentage from a different drug trial and declaring a winner. The participants, duration, doses and analysis may differ. People with type 2 diabetes are not automatically interchangeable with the population in the tirzepatide study discussed in our newsletter.

Those differences do not make comparison pointless. They make a simple ranking less reliable than it looks.

For the person reading at home, a useful habit is to ask whether two results came from the same trial with a direct comparison. If they did not, look for the differences before assuming the numbers settle the question.

How we decide what a new result means

At proof3, we follow the research because it affects questions people bring into the gym. We also see the appeal of a clear answer. Nobody wants every conversation to end in a pile of qualifications.

Still, there are a few questions we want answered before turning a result into advice.

First, who was studied? A group with a particular medical condition may have different needs from someone who wants to lose a small amount of weight. Age, starting body composition and health circumstances matter when considering how relevant a finding might be.

Second, what changed? Weight, fat mass, lean mass, strength, pain and everyday function are all worth studying. We want the claim to name the outcome that was actually measured.

Third, what was the comparison? A placebo group, another medication and a structured exercise program answer different questions. A study that did not test a training intervention cannot tell us exactly what that intervention would have changed.

Finally, what happened over time, including to people who did not complete treatment? The number at the end of a headline rarely carries all of that context with it.

We apply the same care to our own observations. What members tell us and what we see in training matter to our coaching. They are not controlled evidence that establishes which medication works best or why a particular person's result occurred.

For example, a person may change medication, start lifting and improve their food intake within the same few months. Their progress is worth celebrating. It is harder to say exactly how much came from each change.

That is why we want both research and careful follow-up with individuals. They contribute different kinds of information.

What we keep doing while the research develops

Newer medication research does not make the basics of training irrelevant. It gives us more reason to ask how the whole plan fits together.

We are interested in studies that pair weight-loss treatment with structured resistance exercise and nutritional support. We want to know about strength and function as well as body-composition changes. We also want longer follow-up that helps explain what people can maintain.

For someone already working on weight loss, there are practical things to address now. Know your starting point. Discuss food intake with your care team. Make strength training a consistent part of the plan where appropriate. Review changes instead of assuming everything is fine because weight is falling.

If you are considering a medication, take the research questions to your clinician. Ask which findings apply to your situation and what they would monitor. You should be able to discuss both the potential benefits and the uncertainties.

At proof3, our role is to help people train and understand their physical starting point. Our assessment in Scottsdale brings body composition, movement and power into that conversation. It does not determine which medication someone should take.

We want people to lose excess body fat when appropriate and maintain or improve their capabilities along the way. We can be interested in a new drug while continuing to ask what happens to the person using it.

That is what we will keep watching as the research develops.

Scottsdale Strength Training

Live Stronger For Longer

Replace guesswork with data-driven strength and endurance training built around how your body actually moves.

Book Your AssessmentSee how it works

No commitment. A coach will call you back — usually the same day.

Subscribe to our newsletter

Sign up for our newsletter for the latest proof3 news
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Related articles

A member rides an exercise bike in the proof3 studio.
Recovery, Flexibility, Mobility
November 2026

Strength-Training Recovery After 50: How to Plan Between Sessions

Plan time between strength sessions, understand delayed soreness and know when to discuss symptoms with your coach or health-care team.
A proof3 coach spots a member during a barbell squat.
Fitness
November 2026

Progressive Overload: How a Coach Helps You Decide When to Add More

Understand progressive overload, the ways a coach can adjust your training and when holding steady makes sense at proof3 Scottsdale.
A member checks her workout on a training-station tablet.
Fitness
November 2026

How to Tell Whether Your Strength Training Is Working

Track comparable exercises, resistance and repetitions, then use assessment results and coaching to understand changes in your strength.
proof3
Follow proof3 Salt River Gym
proof3 Salt River on Instagramproof3 Training on Facebook
Follow proof3 Online Coaching
proof3 Coaching on Instagramproof3 Coaching on Facebook
Contact Us : info@proof3.com
ContactCareersPrivacy PolicyTerms and Conditions
© 2025 proof3® All Rights Reserved.